Innate Pharma (IPHA) Assets Average (2018 - 2025)

Innate Pharma (IPHA) has 7 years of Assets Average data on file, last reported at $89.1 million in Q4 2025.

• For the quarter ending Q4 2025, Assets Average fell 36.77% year-over-year to $89.1 million; the trailing twelve-month figure through Dec 2025 stood at $89.1 million (down 36.77% YoY), and the FY2025 full-year result was $95.8 million, down 37.6% from the prior year.
• Assets Average for Q4 2025 stood at $89.1 million, down from $111.9 million in the prior quarter.
• Across five years, Assets Average topped out at $343.6 million in Q2 2021 and bottomed at $89.1 million in Q4 2025.
• The 5-year median for Assets Average is $208.5 million (2023), against an average of $215.0 million.
• The widest annual swing landed in 2021, when Assets Average plunged 99.81%; it then decreased 11.92% in 2022.
• A 5-year view of Assets Average shows it stood at $313.3 million in 2021, then slipped by 18.4% to $255.7 million in 2022, then slipped by 20.74% to $202.6 million in 2023, then plunged by 30.46% to $140.9 million in 2024, then tumbled by 36.77% to $89.1 million in 2025.
• The last three Assets Average figures came in at $89.1 million (Q4 2025), $111.9 million (Q2 2025), and $140.9 million (Q4 2024), per Business Quant data.

Peer Comparison